Somaxon Pharmaceuticals Inc. (SOMX) soared last week after the FDA approved its Silenor ... Before the FDA approval, this was a $4.00 stock. It ran to $10.60 before closing at $8.25 last week as major profit taking came into play. Last …
Translation: The upward trend remains intact but there's some disquieting underlying technical deterioration that we must take note ... the economy up to full and steady growth. As for why the stock market is rallying on this lukewarm …
12/10 Gladstone Investment Corporation $GAIN Director Purchases $62,113.20 in Stock.. 12/08 Ask Me Anything ...
Crew Group, Inc. (NYSE: JCG), Netezza Corporation (NYSE: NZ), 3PAR, Inc. (NYSE: PAR), Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), SunPower Corporation (NASDAQ: SPWRA) and Sterling Financial Corp. (NASDAQ: STSA). …
In addition, Zacks Equity Research provides analysis on Mylan Inc. (MYL), Somaxon Pharmaceutical, Inc. (SOMX) and …
Pernix has been active on the acquisition front with the acquisition of Great Southern Laboratories in July 2012 and the merger agreement to acquire Somaxon Pharmaceuticals, Inc. ( SOMX) for $25 million in December 2012. We currently …
Vivendi VIVHY downgraded to underperform from neutral at Exane BNP Paribas. Quicksilver KWK downgraded to Neutral from Buy at UBS on reduced natural gas forecasts and funding concerns. Price target lowered to $11 from $13. Darden …
In the pipeline Somaxon Pharmaceuticals is waiting on an FDA decision on its experimental anti-insomnia drug Silenor. Somaxon (SOMX) chief financial officer Meg McGilley said it's not addictive, which could give it a competitive edge. A …
Paladin received rights to commercialize Silenor in Canada, South America and Africa from Somaxon Pharmaceuticals, Inc. (SOMX) in June 2011. About Paladin Labs Inc. Paladin Labs Inc., headquartered in Montreal, Canada, is a …
Following are the research actions reported by Reuters on Thursday as of 0713 ET ----- ----- STOCK RESEARCH BY ACTION Vertex Pharmaceuticals Goldman Sachs Raises to buy from neutral (VRTX.O ...